Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ERNA
Upturn stock ratingUpturn stock rating

Eterna Therapeutics Inc (ERNA)

Upturn stock ratingUpturn stock rating
$1.84
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ERNA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$1.84
high$

Analysis of Past Performance

Type Stock
Historic Profit -59.95%
Avg. Invested days 19
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 13.62M USD
Price to earnings Ratio -
1Y Target Price 3
Price to earnings Ratio -
1Y Target Price 3
Volume (30-day avg) -
Beta 7.12
52 Weeks Range 1.75 - 39.45
Updated Date 06/29/2025
52 Weeks Range 1.75 - 39.45
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -32.7

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -2652.9%

Management Effectiveness

Return on Assets (TTM) -32.42%
Return on Equity (TTM) -2264.31%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 14647264
Price to Sales(TTM) 25.45
Enterprise Value 14647264
Price to Sales(TTM) 25.45
Enterprise Value to Revenue 27.38
Enterprise Value to EBITDA -0.29
Shares Outstanding 7361200
Shares Floating 1664157
Shares Outstanding 7361200
Shares Floating 1664157
Percent Insiders 61.04
Percent Institutions 1.35

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Eterna Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Eterna Therapeutics Inc. is a biotechnology company focusing on developing messenger RNA (mRNA) based therapies. The company leverages mRNA technology to develop novel treatments for various diseases, including cancer and genetic disorders. Specific founding year and milestones are not widely and publicly available.

business area logo Core Business Areas

  • mRNA Therapeutics Development: Eterna Therapeutics develops mRNA-based drugs designed to address unmet medical needs across diverse therapeutic areas. This includes preclinical and clinical research.
  • Drug Delivery Technologies: The company focuses on improving drug delivery to ensure that mRNA therapeutics reach their intended targets effectively.
  • Research and Development: Eterna Therapeutics dedicates resources to researching and developing new mRNA technologies and therapeutic applications.

leadership logo Leadership and Structure

Details about the specific leadership team structure are not widely accessible to the public but typical biotechnology firms have a C-suite including a CEO, CSO and CFO.

Top Products and Market Share

overview logo Key Offerings

  • mRNA-Based Cancer Therapies (Preclinical): Eterna Therapeutics is developing mRNA-based cancer therapies; however, these are in the preclinical stage, so market share and revenue data are not yet available. Competitors include Moderna (MRNA), BioNTech (BNTX), and CureVac (CVAC).
  • mRNA-Based Genetic Disorder Therapies (Preclinical): Similarly, Eterna Therapeutics is developing mRNA therapies for genetic disorders in the preclinical stage. Competitors include Moderna (MRNA), BioNTech (BNTX), and Sarepta Therapeutics (SRPT).

Market Dynamics

industry overview logo Industry Overview

The mRNA therapeutics market is experiencing rapid growth driven by the success of mRNA vaccines and the potential of mRNA technology to treat a wide range of diseases. Key trends include advancements in drug delivery systems and increasing investment in mRNA research and development.

Positioning

Eterna Therapeutics is positioned as a player in the mRNA therapeutics space, competing with larger and more established companies. Its competitive advantage would depend on proprietary technologies and novel therapeutic applications.

Total Addressable Market (TAM)

The global mRNA therapeutics market is projected to reach billions of dollars in the coming years. Eterna Therapeutics's positioning within this TAM will depend on the success of its preclinical and clinical programs. Exact TAM numbers vary depending on the source.

Upturn SWOT Analysis

Strengths

  • Focus on mRNA technology
  • Potential for novel therapies
  • Experienced research team
  • Strong intellectual property (potentially)

Weaknesses

  • Early stage of development
  • Limited financial resources compared to larger competitors
  • Dependence on preclinical success
  • Lack of approved products

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Advancements in mRNA delivery technologies
  • Expansion into new therapeutic areas
  • Positive clinical trial results

Threats

  • Competition from established biotechnology companies
  • Regulatory hurdles
  • Clinical trial failures
  • Intellectual property disputes

Competitors and Market Share

competitor logo Key Competitors

  • MRNA
  • BNTX
  • CVAC
  • SRPT

Competitive Landscape

Eterna Therapeutics faces significant competition from well-established mRNA companies. Success will depend on unique technologies and therapeutic breakthroughs.

Growth Trajectory and Initiatives

Historical Growth: Historical growth data is not publicly available.

Future Projections: Future growth projections are difficult to determine without public financial data. Analyst estimates are not readily available.

Recent Initiatives: Recent initiatives likely include advancing preclinical programs and seeking partnerships. Public details are limited.

Summary

Eterna Therapeutics is a private mRNA-focused biotechnology company in the early stages of development. Its potential lies in its focus on mRNA technologies for novel therapeutics, but it faces significant challenges from larger competitors. Securing partnerships and demonstrating preclinical success are critical for future growth and survival. Significant public data is missing given its private status.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website (limited information)
  • Industry reports
  • Publicly available news and press releases

Disclaimers:

Information is based on limited publicly available data and may not be entirely accurate. Market share estimates are approximate and based on the broader mRNA therapeutics market. The AI-based rating is an estimate and should not be considered investment advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Eterna Therapeutics Inc

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 1992-10-19
CEO, President & Director Mr. Sanjeev Luther
Sector Healthcare
Industry Biotechnology
Full time employees 6
Full time employees 6

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.